Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose of review To determine usefulness and versatility of hydrochlorothiazide (HCTZ) relative to other thiazide diuretics in the treatment of hypertension. Recent findings HCTZ was found to be less potent in lowering blood pressure (BP) than other thiazide diuretics, including chlorthalidone (CTD) and bendroflumethiazide. A recent meta-analysis also suggested HCTZ (12.5-25mg daily) to be less potent than antihypertensive agents from several other classes, including angiotensinconverting enzyme inhibitors, angiotensin-receptor blockers, and calcium antagonists. The risk of hyponatremia, hypokalemia, and hyperuricemia associated with HCTZ was lower than with CTD, while the risk of gouty arthritis was similar. Despite lower risks of metabolic side-effects, meta-analysis of clinical trials showed that, for any given difference in achieved clinic SBP, HCTZ therapy was associated with 18% higher adverse cardiovascular events when compared with CTD. Summary Increasing evidence suggests inferiority of HCTZ in lowering BP and cardiovascular outcomes in hypertensive patients when compared with other drugs in the same class, particularly CTD and indapamide. Thus, HCTZ is neither more useful nor more versatile than other thiazide diuretics. CTD and indapamide should be preferred over HCTZ in most hypertensive patients when diuretics are required for treatment of hypertension.

Original languageEnglish (US)
Pages (from-to)361-365
Number of pages5
JournalCurrent Opinion in Cardiology
Volume30
Issue number4
DOIs
StatePublished - Aug 24 2015

Fingerprint

Sodium Chloride Symporter Inhibitors
Hydrochlorothiazide
Chlorthalidone
Indapamide
Meta-Analysis
Bendroflumethiazide
Gouty Arthritis
Blood Pressure
Hypertension
Hyperuricemia
Hypokalemia
Hyponatremia
Angiotensin Receptor Antagonists
Enzyme Inhibitors
Diuretics
Antihypertensive Agents
Therapeutics
Clinical Trials
Calcium

Keywords

  • Chlorthalidone
  • Hydrochlorothiazide
  • Hypertension
  • Thiazide diuretics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic. / Vongpatanasin, Wanpen.

In: Current Opinion in Cardiology, Vol. 30, No. 4, 24.08.2015, p. 361-365.

Research output: Contribution to journalArticle

@article{937e68a131714d54a19b963ef7e39718,
title = "Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic",
abstract = "Purpose of review To determine usefulness and versatility of hydrochlorothiazide (HCTZ) relative to other thiazide diuretics in the treatment of hypertension. Recent findings HCTZ was found to be less potent in lowering blood pressure (BP) than other thiazide diuretics, including chlorthalidone (CTD) and bendroflumethiazide. A recent meta-analysis also suggested HCTZ (12.5-25mg daily) to be less potent than antihypertensive agents from several other classes, including angiotensinconverting enzyme inhibitors, angiotensin-receptor blockers, and calcium antagonists. The risk of hyponatremia, hypokalemia, and hyperuricemia associated with HCTZ was lower than with CTD, while the risk of gouty arthritis was similar. Despite lower risks of metabolic side-effects, meta-analysis of clinical trials showed that, for any given difference in achieved clinic SBP, HCTZ therapy was associated with 18{\%} higher adverse cardiovascular events when compared with CTD. Summary Increasing evidence suggests inferiority of HCTZ in lowering BP and cardiovascular outcomes in hypertensive patients when compared with other drugs in the same class, particularly CTD and indapamide. Thus, HCTZ is neither more useful nor more versatile than other thiazide diuretics. CTD and indapamide should be preferred over HCTZ in most hypertensive patients when diuretics are required for treatment of hypertension.",
keywords = "Chlorthalidone, Hydrochlorothiazide, Hypertension, Thiazide diuretics",
author = "Wanpen Vongpatanasin",
year = "2015",
month = "8",
day = "24",
doi = "10.1097/HCO.0000000000000178",
language = "English (US)",
volume = "30",
pages = "361--365",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic

AU - Vongpatanasin, Wanpen

PY - 2015/8/24

Y1 - 2015/8/24

N2 - Purpose of review To determine usefulness and versatility of hydrochlorothiazide (HCTZ) relative to other thiazide diuretics in the treatment of hypertension. Recent findings HCTZ was found to be less potent in lowering blood pressure (BP) than other thiazide diuretics, including chlorthalidone (CTD) and bendroflumethiazide. A recent meta-analysis also suggested HCTZ (12.5-25mg daily) to be less potent than antihypertensive agents from several other classes, including angiotensinconverting enzyme inhibitors, angiotensin-receptor blockers, and calcium antagonists. The risk of hyponatremia, hypokalemia, and hyperuricemia associated with HCTZ was lower than with CTD, while the risk of gouty arthritis was similar. Despite lower risks of metabolic side-effects, meta-analysis of clinical trials showed that, for any given difference in achieved clinic SBP, HCTZ therapy was associated with 18% higher adverse cardiovascular events when compared with CTD. Summary Increasing evidence suggests inferiority of HCTZ in lowering BP and cardiovascular outcomes in hypertensive patients when compared with other drugs in the same class, particularly CTD and indapamide. Thus, HCTZ is neither more useful nor more versatile than other thiazide diuretics. CTD and indapamide should be preferred over HCTZ in most hypertensive patients when diuretics are required for treatment of hypertension.

AB - Purpose of review To determine usefulness and versatility of hydrochlorothiazide (HCTZ) relative to other thiazide diuretics in the treatment of hypertension. Recent findings HCTZ was found to be less potent in lowering blood pressure (BP) than other thiazide diuretics, including chlorthalidone (CTD) and bendroflumethiazide. A recent meta-analysis also suggested HCTZ (12.5-25mg daily) to be less potent than antihypertensive agents from several other classes, including angiotensinconverting enzyme inhibitors, angiotensin-receptor blockers, and calcium antagonists. The risk of hyponatremia, hypokalemia, and hyperuricemia associated with HCTZ was lower than with CTD, while the risk of gouty arthritis was similar. Despite lower risks of metabolic side-effects, meta-analysis of clinical trials showed that, for any given difference in achieved clinic SBP, HCTZ therapy was associated with 18% higher adverse cardiovascular events when compared with CTD. Summary Increasing evidence suggests inferiority of HCTZ in lowering BP and cardiovascular outcomes in hypertensive patients when compared with other drugs in the same class, particularly CTD and indapamide. Thus, HCTZ is neither more useful nor more versatile than other thiazide diuretics. CTD and indapamide should be preferred over HCTZ in most hypertensive patients when diuretics are required for treatment of hypertension.

KW - Chlorthalidone

KW - Hydrochlorothiazide

KW - Hypertension

KW - Thiazide diuretics

UR - http://www.scopus.com/inward/record.url?scp=84942603045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942603045&partnerID=8YFLogxK

U2 - 10.1097/HCO.0000000000000178

DO - 10.1097/HCO.0000000000000178

M3 - Article

VL - 30

SP - 361

EP - 365

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 4

ER -